A new Yale School of Medicine and Icahn School of Medicine at Mount Sinai study found that people who have experienced brain fog, confusion, pain, and extreme fatigue for months or longer after being infected with COVID-19 have different immune and hormonal responses to the virus.
These different responses may help scientists pinpoint the origins and maybe solutions for the frequently debilitating condition that has impacted millions worldwide. The U.S. estimates 7.5% of SARS-CoV-2 infections develop long-term COVID.
“If you are a doctor doing routine lab work on these patients, you are not going to find these signals,” said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale and co-senior author of the paper.
The findings appeared in Nature on Sept. 25.
The study examined blood samples from 268 persons who had long-term COVID symptoms for an average of one year, had recovered from COVID-19, or had no past infections. The researchers found substantial changes in circulating antibodies and other immune system cells between long-COVID patients and others.
Long-term COVID patients have higher levels of antibodies that combat non-COVID-19 viruses, including Epstein-Barr virus, a human herpesvirus related to many malignancies. These individuals also had significantly reduced cortisol levels, a stress hormone secreted by the adrenal glands.
The scientists say these data indicate fundamental molecular processes related with chronic COVID, but the variety of individual reactions makes creating treatments difficult.
“There is no ‘silver bullet’ for treating long COVID, because it is an illness that infiltrates complex systems such as the immune and hormonal regulation,” said co-senior author David Putrino, a professor of rehabilitation and human performance at Icahn Mount Sinai and director of the Cohen Center for Recovery From Complex Chronic Illness
Iwasaki said the new findings may contribute in the development of novel diagnostics and treatments.
“Once we have more information on these signals, we can start to think about designing the right trials to treat this condition,” she said.
more recommended stories
-
Efficient AI-Driven Custom Protein Design Method
Protein design seeks to develop personalized.
-
Human Cell Atlas: Mapping Biology for Precision Medicine
In a recent perspective article published.
-
Preterm Birth Linked to Higher Mortality Risk
A new study from Wake Forest.
-
Heart Failure Risk Related to Obesity reduced by Tirzepatide
Tirzepatide, a weight-loss and diabetes medicine,.
-
Antibiotic Activity Altered by Nanoplastics
Antibiotic adsorption on micro- and nano-plastics.
-
Cocoa Flavonols: Combat Stress & Boost Vascular Health
Cocoa Flavonols on combatting Stress: Stress.
-
AI Predicts Triple-Negative Breast Cancer Prognosis
Researchers at Sweden’s Karolinska Institutet explored.
-
Music Therapy: A Breakthrough in Dementia Care?
‘Severe’ or ‘advanced’ dementia is a.
-
FasL Inhibitor Asunercept Speeds COVID-19 Recovery
A new clinical trial demonstrates that.
-
Gut Health and Disease is related to microbial load
When it comes to Gut Health,.
Leave a Comment